Protagenic Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Protagenic Therapeutics has a total shareholder equity of $6.4M and total debt of $369.1K, which brings its debt-to-equity ratio to 5.8%. Its total assets and total liabilities are $7.7M and $1.3M respectively.
Key information
5.8%
Debt to equity ratio
US$369.13k
Debt
| Interest coverage ratio | n/a |
| Cash | US$7.65m |
| Equity | US$6.41m |
| Total liabilities | US$1.25m |
| Total assets | US$7.67m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MBP's short term assets ($7.7M) exceed its short term liabilities ($1.3M).
Long Term Liabilities: MBP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MBP has more cash than its total debt.
Reducing Debt: MBP's debt to equity ratio has increased from 0% to 5.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MBP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MBP has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 15.5% each year